Rates directly age-standardised to the 2001 Australian population.

Analyses by state and territory, remoteness and Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-economic Disadvantage (IRSD) are based on the state or territory and Statistical Local Area (SLA) of the person at the time of their diagnosis. 

Rates that are considered unstable and should be interpreted with caution will be noted. Rates that are considered very unstable will not be published.

Presented as:

• a number (for state and territory by cancer type disaggregations) 
• per 100,000.

100,000 × (Numerator ÷ Denominator)

For melanoma, bowel and lung cancer: Number of new cases in the reported year.

For cervical and breast cancer in females: Number of new cases in females in the reported year.

For melanoma, bowel and lung cancer: Total population.

2011—Nationally (for each cancer type), by 2011 Socio-Economic Indexes for Areas (SEIFA) Index of Relative Socio-economic Disadvantage (IRSD) deciles.

2011—State and territory (for each cancer type), by:

• remoteness (Australian Statistical Geography Standard (ASGS) Remoteness Structure).
• 2011 SEIFA IRSD quintiles.

2007, 2008, 2009, 2010 (resupplied for updated Indigenous ERP), 2011—State and territory (for each cancer type), by:

• Indigenous status.

Some disaggregation may result in numbers too small for publication.

Disaggregation by SEIFA and remoteness data are subject to availability of suitable population data.

Most recent data available for 2015 National Healthcare Agreement (NHA) performance reporting: 2011.

2011 data for NSW and ACT will not be available for inclusion and will be estimated for the state and territory by cancer type disaggregation. 2011 estimated data for NSW and ACT will not be disaggregated by Indigenous status, remoteness or SEIFA IRSD quintiles.

2010 incidence data will be resupplied to include incidence rates for New South Wales and the Australian Capital Territory, which were supplied as estimates in the 2014 report.